covid
Buscar en
Revista Colombiana de Cancerología
Toda la web
Inicio Revista Colombiana de Cancerología Tumores estromales gastrointestinales (GIST) en el Instituto Nacional de Cancero...
Journal Information
Vol. 15. Issue 4.
Pages 202-211 (January 2011)
Share
Share
Download PDF
More article options
Vol. 15. Issue 4.
Pages 202-211 (January 2011)
Full text access
Tumores estromales gastrointestinales (GIST) en el Instituto Nacional de Cancerología, Bogota D.C., Colombia 2000-2008
Gastrointestinal Stromal Tumors (GIST) at the National Cancer Institute, Bogota D.C., Colombia 2000-2008
Visits
2765
Ricardo Oliveros1,
Corresponding author
roliveros4@yahoo.es

Correspondencia Grupo Cirugía Gastrointestinal y Endoscopia Digestiva, Instituto Nacional de Cancerología. Avenida 1a No 9-85. Bogota, Colombia Tel.: 3341111, ext. 5405.
, Álvaro Pío Quintero2, Ricardo Sánchez3,5, Jorge Andrés Mesa4
1 Grupo de Cirugía Gastrointestinal y Endoscopia Digestiva, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
2 Grupo de Gastroenterología y Endoscopia Digestiva, Hospital San Rafael, Tunja, Colombia
3 Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
4 Grupo de Patología, Instituto Nacional de Cancerología, Bogotá D.C., Colombia
5 Universidad Nacional de Colombia, Bogotá D.C., Colombia
This item has received
Article information
Resumen
Objetivo

Describir las características demográficas, clínicas y patológicas, así como el diagnóstico, el tratamiento y el seguimiento de los pacientes con tumores estromales gastrointestinales (GIST) del Instituto Nacional de Cancerología (INC) durante el periodo comprendido entre 2000 y 2008.

Métodos

Estudio retrospectivo, de 39 pacientes con diagnóstico de GIST, donde se analizan las características clínicas los diagnósticos patológico y de inmunohistoquímica, al igual que los factores pronósticos, como tamaño, conteo mitótico y localización. Se revisa los manejos quirúrgico y médico, el seguimiento y la recurrencia, de acuerdo con la localización de las lesiones.

Resultados

Se incluyó a 39 pacientes, con edad promedio de 53 años. La localización más habitual fue el estómago, con 16 casos, seguida del intestino delgado, con 9. De los pacientes, 24 presentaban lesiones mayores a 10cm y, 19 con lesiones que microscópicamente mostraban menos de 5 mitosisx50 campos. Excepto una, todas las lesiones fueron positivas para CD117. El síntoma más habitual fue el dolor abdominal. De los 39 pacientes, 7 tenían metástasis al momento del diagnóstico. Al 43,7% de los pacientes se les tomó biopsia preoperatoria, y 38 pacientes fueron llevados a cirugía; 8 de ellos, por obstrucción intestinal con localización en el intestino delgado. El tiempo de seguimiento osciló entre 2 y 72 meses. Se presentaron 16 recaídas, con una tasa de 1,26x100 pacientes. La supervivencia media fue de 48,53 meses.

Conclusiones

Los GIST son un grupo de tumores de mayor diagnóstico cada día, debido a la sospecha clínica y al diagnóstico por inmunohistoquímica. El manejo es, primordialmente, quirúrgico, pero en la actualidad la adyuvancia y la neoadyuvancia con ITK son parte del manejo de esta patología.

Palabras clave:
Tumores del estroma gastrointestinal
pronóstico
resultado del tratamiento
marcadores biológicos de tumor
proteínas protooncogénicas c-kit
antígeno Ki-67.
Abstract
Objective

To describe the demographic, clinical and pathological characteristics, as well as diagnosis, treatment and follow up in patients with gastrointestinal stromal tumors (GIST) at the National Cancer Institute (NCI) between 2000 and 2008.

Methods

A retrospective study was carried out on 39 patients diagnosed with GIST in which the diagnostic pathology and immunohistochemical clinical characteristics were analyzed, as were prognostic factors such as size, mitotic count and localization. Surgical and medical procedures along with follow up and recurrence were reviewed in relation to lesion localization.

Results

The study included 39 patients with an average age of 53 years. Most common localization was the stomach (16 cases), followed by the small intestine (9 cases). Out of total number of patients, 24 had lesions greater than 10cm. and 19 had lesions less than 5 mitosisx50 fields. All but one lesion tested CD117 positive. Abdominal pain was the most common symptom. Of the 39 patients, 7 had metastasis at time of diagnosis. Preoperative biopsy was taken on 43.7% of patients, and 38 patients underwent surgery; 8 of whom for intestinal obstruction in the small intestine. Follow up ranged from 2 to 72 months. Relapse occurred in 16 cases, for a rate of 1.26 per 100 patients. Median survival rate was 48.53 months.

Conclusions

GISTs make up a group of tumors with ever increasing diagnosis due to clinical suspicion and immunohistochemical diagnosis. Treatment is primarily surgical, but adjuvant and neo-adjuvant ITK treatment are currently used to treat this pathology.

Key words:
Gastrointestinal Stromal Tumors
Prognosis
Treatment Outcome
Tumor Markers
Biological
Proto-Oncogene Proteins c-kit
Ki-67 Antigen.
Full text is only aviable in PDF
Referencias
[1.]
M. Miettinen, J. Lasota.
Gastrointestinal stromal tumors: definition, clinical histological, immunohistochemical and molecular genetics features and differential diagnosis.
Virchows Arch, 438 (2001), pp. 1-12
[2.]
T. Nishida, S. Hirota.
Biological and clinical review of stromal tumors of the gastrointestinal tract.
Histol Histopathol, 15 (2000), pp. 1293-1301
[3.]
T. Golden, A.P. Stout.
Smooth muscle tumors of the gastrointestinal tract and retroperitoneal tissues.
Surg Gynecol Obstet, 73 (1941), pp. 784-810
[4.]
G.F. Starr, M.B. Dockerty.
Leiomyomas and leiomiosarcomas of the small intestine.
Cancer, 8 (1955), pp. 101-111
[5.]
G.A. Herrera, L. Cerezo, J.E. Jones, et al.
Malignant small bowell neoplasm of enteric plexos derivation (plexosarcoma). Light and electron microscopic study confirming the origin of the neoplasm.
Dig Dis Sci, 29 (1984), pp. 275-284
[6.]
G.Y. Lauwers, R.A. Erlandson, E.S. Casper, et al.
Gastrointestinal autonomic nerve tumors: A clinicopathologic, immunohistochemical and ultrastructural study of 12 cases.
Am J Surg Pathol, 17 (1993), pp. 887-897
[7.]
M.T. Mazur, H.B. Clark.
Gastric stromal tumors: reappraisal of histogenesis.
Am J Surg Pathol, 7 (1983), pp. 507-519
[8.]
S. Hirota, K. Isozaki, Y. Moriyama, et al.
Gain of function mutations of c-kit in human gastrointestinal stromal tumors.
Science, 279 (1998), pp. 577-580
[9.]
M. Miettinen, J. Lasota.
Gastrointestinal stromal tumors: review on morphology, molecular pathology and differential diagnosis.
Arch Pathol Lab Med, 130 (2006), pp. 1466-1478
[10.]
C.D. Fletcher, J. Berman, C. Corless, et al.
Diagnosis of gastrointestinal stromal tumors: a consensus approach.
Hum Pathol, 33 (2002), pp. 459-465
[11.]
Y. Shinomura, K. Kinoshita, S. Tsutsui, et al.
Pathophisiology, diagnosis and treatment of gastrointestinal stromal tumors.
J Gastroenterol, 40 (2005), pp. 775-780
[12.]
R.P. DeMatteo, J.J. Lewis, D. Leung, et al.
Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors of survival.
Ann Surg, 231 (2000), pp. 51-58
[13.]
N. You, R. DeMatteo.
Gastrointestinal stromal tumor: surgery Gastrointestinal Oncology.
Evidence and Analysis, 28 (2007), pp. 337-350
[14.]
G. Gomez, M. Lombo, G. Prieto, et al.
Tumor estromal gastrointestinal (GIST) Presentación de dos casos.
Rev Col Gastroenterol, 19 (2004), pp. 137-142
[15.]
C.A. Vargas, A.F. Cardona, H. Carranza, et al.
Tumores del estromal gastrointestinal (GIST) Experiencia en dos instituciones hospitalarias de Bogotá DC. Colombia. (Estudio del Oncol Group).
Rev Col Gastroenterol, 23 (2008), pp. 213-223
[16.]
J. Heikki.
Current perspectives on the epidemiology of gastrointestinal stromal tumors.
Eur J Cancer, 4 (2006), pp. 4-9
[17.]
J. Blay, M. Von Mehren, M. Blackstein.
Perspective on update treatment guidelines for patients with gastrointestinal stromal tumors.
Cancer, 116 (2010), pp. 5126-5137
[18.]
National Cancer Institute at the National Institutes of health (NIH). Gastrointestinal stromal tumors (PDQ®). Health professional version [internet]. [citado: 15 de abril del 2011]. Disponible en: http://www.cancer.gov/cancertopics/.
[19.]
M. Scarpa, M. Bertin, C. Ruffolo, et al.
A systematic review on the clinical diagnosis of gastrointestinal stromal tumors.
J Surg Oncol, 98 (2008), pp. 384-392
[20.]
M. Miettinen, J.M. Monihan, M. Salormo-Rikala, et al.
Gastrointestinal stromal tumors/smooth mucle tumors (GIST) primary in the omentum and mesentery: a clinicopathologic and immunohistochemical study of 26 cases.
Am J Surg Pathol, 23 (1999), pp. 1109-1118
[21.]
J.D. Reith, J.R. Goldblum, R.H. Lyles, et al.
Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome.
Mod Pathol, 13 (2000), pp. 577-585
[22.]
G.D. Demetri, M. von Mehren, C.R. Antonescu, et al.
NCCN task force report: update on the management of patients with gastrointestinal stromal tumors.
JNCCN, 8 (2010), pp. S1-S44
[23.]
A. Poveda, V. Artigas, A. Casado, et al.
Guía de práctica clínica en los tumores estromales gastrointestinales (GIST) Actualización.
Cir Esp, 84 (2008), pp. 1-21
[24.]
C.P. Raut, J.A. Morgan, S.W. Ashley.
Current issues in gastrointestinal stromal tumors: incidence, molecular biology and contemporary treatment of localized and advanced disease.
Curr Opin Gastroenterol, 23 (2007), pp. 149-158
[25.]
J.A. Fernández, M. Sánchez Canovas, P. Parrilla.
Controversias en el tratamiento de los tumores del estroma gastrointestinal (GIST) primarios.
[26.]
S. Alberto, P. Sánchez, M. Oliveira, et al.
Tumores del estromal gastrointestinal Estudio retrospectivo de 43 casos.
Rev Esp Enferm Dig, 100 (2008), pp. 696-700
[27.]
P. Roberts, B. Eisenberg.
Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease.
Eur J Cancer, 38 (2002), pp. S37-S38
[28.]
R. Quek, S. George.
Gastrointestinal stromal tumor: a clinical overview.
Hematol Oncol Clin N Am, 23 (2009), pp. 69-76
[29.]
Guía Médica.
Diagnóstico y tratamiento. Tumores estromales gastrointestinales (GIST).
Novartis Oncology, (2010),
[30.]
M. Miettinen, J. Lasota.
Gastrointestinal stromal tumors: pathology and prognosis at different sites.
Semin Diagn Pathol, 23 (2006), pp. 70-83
[31.]
P. Pisters, S. Patel.
Gastrointestinal stromal tumors: current management.
J Surg Oncol, 102 (2010), pp. 530-538
[32.]
A. Nowain, H. Bhakta, S. Pais, et al.
Gastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis.
J Gastroenterol Hepatol, 20 (2005), pp. 818-824
[33.]
P. Gervaz, O. Huber, P. Morel.
Surgical management of gastrointestinal stromal tumors.
British J Surg, 96 (2009), pp. 567-578
[34.]
H. Joensuu, P.J. Roberts, S. Rikalam, et al.
Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastastic gastrointestinal Stromal tumor.
N Eng J Med, 344 (2001), pp. 1052-1056
[35.]
P. Reichardt, J. Blay, M. von Mehren.
Towards global consensus in the treatment of gastrointestinal stromal tumor.
Expert Rev Anticancer Ther, 10 (2010), pp. 221-232
[36.]
K. Sjölund, A. Anderson, E. Nilsson, et al.
Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
World J Surg, 34 (2010), pp. 2090-2097
Copyright © 2011. Instituto Nacional de Cancerología
Article options